Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Agile Therapeutics Inc (AGRX)

Agile Therapeutics Inc (AGRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 1,097
  • Shares Outstanding, K 2,964
  • Annual Sales, $ 10,880 K
  • Annual Income, $ -25,410 K
  • 60-Month Beta 1.51
  • Price/Sales 0.05
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade AGRX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -21.33
  • Most Recent Earnings $-1.47 on 11/09/23
  • Latest Earnings Date 03/28/24 [BMO]
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/23
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -9.00
  • Growth Rate Est. (year over year) +11,200.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.2000 +66.50%
on 03/26/24
0.8780 -62.07%
on 03/04/24
-0.4355 (-56.67%)
since 02/28/24
3-Month
0.2000 +66.50%
on 03/26/24
1.9750 -83.14%
on 01/02/24
-1.5870 (-82.66%)
since 12/28/23
52-Week
0.2000 +66.50%
on 03/26/24
12.1450 -97.26%
on 03/30/23
-10.7220 (-96.99%)
since 03/28/23

Most Recent Stories

More News
Agile Therapeutics: Q4 Earnings Snapshot

Agile Therapeutics: Q4 Earnings Snapshot

AGRX : 0.3330 (-10.00%)
Agile Therapeutics: Q3 Earnings Snapshot

Agile Therapeutics: Q3 Earnings Snapshot

AGRX : 0.3330 (-10.00%)
Why Shares of Agile Therapeutics Jumped This Week

The women's healthcare company got an analyst upgrade.

AGRX : 0.3330 (-10.00%)
Agile Therapeutics: Q2 Earnings Snapshot

Agile Therapeutics: Q2 Earnings Snapshot

AGRX : 0.3330 (-10.00%)
Blue Bird, First Solar rise; Harrow Health, Telesis Bio fall

Stocks that traded heavily or had substantial price changes Friday: Blue Bird, First Solar rise; Harrow Health, Telesis Bio fall

NWSA : 26.31 (+0.08%)
AGRX : 0.3330 (-10.00%)
FSLR : 168.14 (+0.41%)
SPB : 89.33 (+0.47%)
BLBD : 37.79 (-0.16%)
Agile Therapeutics: Q1 Earnings Snapshot

Agile Therapeutics: Q1 Earnings Snapshot

AGRX : 0.3330 (-10.00%)
Agile Therapeutics: Q4 Earnings Snapshot

Agile Therapeutics: Q4 Earnings Snapshot

AGRX : 0.3330 (-10.00%)
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?

Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.

ARDX : 7.43 (+0.27%)
AGRX : 0.3330 (-10.00%)
TEVA Beats Q4 Earnings Estimates, Sales Miss & Stock Down

TEVA reports mixed Q4 results, beating earnings estimates, while sales slightly miss estimates. Stock down post earnings release.

TEVA : 14.16 (-1.87%)
ADMA : 6.64 (-1.48%)
AGRX : 0.3330 (-10.00%)
ETNB : 11.07 (-2.12%)
Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?

Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year.

ARDX : 7.43 (+0.27%)
AGRX : 0.3330 (-10.00%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Key Turning Points

3rd Resistance Point 0.5107
2nd Resistance Point 0.4643
1st Resistance Point 0.4172
Last Price 0.3330
1st Support Level 0.3237
2nd Support Level 0.2773
3rd Support Level 0.2302

See More

52-Week High 12.1450
Fibonacci 61.8% 7.5820
Fibonacci 50% 6.1725
Fibonacci 38.2% 4.7630
Last Price 0.3330
52-Week Low 0.2000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar